A Study of Peri-implant Tissue Clinical Parameters in Patients Starting Anti-osteoporosis Medication After Existing Implant Function: a Prospective Cohort Study

Overview

Journal Int J Implant Dent

Publisher Springer

Specialty Dentistry

Date 2024 Nov 5

PMID 39500812

Authors

Keisuke Seki

Takaaki Tamagawa

Hiroyasu Yasuda

Soichiro Manaka

Daisuke Akita

Atsushi Kamimoto

Yoshiyuki Hagiwara

Affiliations

Soon will be listed here.

Abstract

Purpose: Recently, rare cases of medication-related peri-implant osteonecrosis of the jaw (PI-MRONJ) have been reported. In patients with functional implants who begin using anti-osteoporosis medications (AOMs) after implantation, PI-MRONJ is unpredictable and poses a significant threat to the patient. In this study, we aimed to evaluate the impact of AOMs on peri-implant tissues and to examine risk factors for peri-implantitis, a presumed trigger for PI-MRONJ.

Methods: The study cohort consisted of patients who underwent implant maintenance treatment between January 2016 and February 2024. Patients were divided into AOM users (AOM group) and controls (control group). Clinical parameters were statistically evaluated, including implant probing depth (iPPD), implant bleeding on probing (iBoP), marginal bone resorption (MBL), and mandibular cortical index (MCI) measured at baseline and at the last visit. Risk factors were examined by multivariate analysis for adjusted odds ratios.

Results: A total of 94 patients (35 male, 59 female) with 270 implants were recruited. The AOM group had 93 implants (24 patients). Comparison of clinical parameters showed significantly greater changes in iBoP (p = 0.000768) and MBL (p = 0.000863) scores over time in the AOM group than in the control group. Risk factors for peri-implantitis were a history of moderate or severe periodontal disease (OR: 15.8, 95% CI 3.6-69.3, p = 0.000256) and MCI class 3 (OR: 3.3, 95% CI 1.4-7.8, p = 0.00534).

Conclusions: In implant treatment of AOM users, special attention should be paid to local inflammation, which is presumed to be the cause of PI-MRONJ.

References

Javed F, Almas K . Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol. 2010; 81(4):479-84. DOI: 10.1902/jop.2009.090587. View

Seki K, Kobayashi A, Takahashi N, Kamimoto A . Medication-related osteonecrosis of the jaw in a patient with rheumatoid arthritis with suspected involvement of methotrexate and tocilizumab. J Dent Sci. 2024; 19(4):2428-2429. PMC: 11437342. DOI: 10.1016/j.jds.2024.07.024. View

Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A . Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2014; 72(10):1937.e1-8. DOI: 10.1016/j.joms.2014.04.037. View

Hong S, Yang B, Yoo D, Kim S, Choi H, Byun S . Analysis of the relationship between periodontitis and osteoporosis/fractures: a cross-sectional study. BMC Oral Health. 2021; 21(1):125. PMC: 7968237. DOI: 10.1186/s12903-021-01496-1. View

Yong C, Sng T, Choo S, Chew J, Islam I . Implant presence-triggered osteonecrosis: A scoping review. J Stomatol Oral Maxillofac Surg. 2024; 125(5):101759. DOI: 10.1016/j.jormas.2024.101759. View

Nashi M, Kishimoto H, Kobayashi M, Tachibana A, Suematsu M, Fujiwara S . Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan. J Dent Sci. 2023; 18(3):1156-1163. PMC: 10316444. DOI: 10.1016/j.jds.2022.10.030. View

Seki K, Hagiwara Y . Peri-implantitis-induced medication-related osteonecrosis of the jaw: A case report. J Dent Sci. 2022; 17(1):576-577. PMC: 8739731. DOI: 10.1016/j.jds.2021.07.014. View

Koldsland O, Scheie A, Aass A . Prevalence of peri-implantitis related to severity of the disease with different degrees of bone loss. J Periodontol. 2010; 81(2):231-8. DOI: 10.1902/jop.2009.090269. View

Anastasilakis A, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan A . Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab. 2021; 107(5):1441-1460. PMC: 9016445. DOI: 10.1210/clinem/dgab888. View

10.

Schwarz F, Becker K, Lukman F, Muller K, Sarabhai V, Rauch N . Influence of antiresorptive/antiangiogenic therapy on the extension of experimentally induced peri-implantitis lesions. Clin Oral Investig. 2023; 27(6):3009-3019. PMC: 10264532. DOI: 10.1007/s00784-023-04904-8. View

11.

Ryu J, Kim H, Kwon Y . Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study. Clin Oral Implants Res. 2021; 32(4):437-447. DOI: 10.1111/clr.13713. View

12.

Seki K, Hasuike A, Hagiwara Y . Clinical Evaluation of the Relationship Between Systemic Disease and the Time of Onset of Peri-Implantitis: A Retrospective Cohort Study. J Oral Implantol. 2022; 49(1):55-61. DOI: 10.1563/aaid-joi-D-21-00186. View

13.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

14.

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D . Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88(6):2095-105. PMC: 295810. DOI: 10.1172/JCI115539. View

15.

Leslie W, Lix L, Binkley N . Osteoporosis treatment considerations based upon fracture history, fracture risk assessment, vertebral fracture assessment, and bone density in Canada. Arch Osteoporos. 2020; 15(1):93. DOI: 10.1007/s11657-020-00775-8. View

16.

Korfage A, Raghoebar G, Meijer H, Vissink A . Patients' expectations of oral implants: a systematic review. Eur J Oral Implantol. 2018; 11 Suppl 1:S65-S76. View

17.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

18.

Sher J, Kirkham-Ali K, Luo J, Miller C, Sharma D . Dental Implant Placement in Patients With a History of Medications Related to Osteonecrosis of the Jaws: A Systematic Review. J Oral Implantol. 2020; 47(3):249-268. DOI: 10.1563/aaid-joi-D-19-00351. View

19.

Berglundh T, Armitage G, Araujo M, Avila-Ortiz G, Blanco J, Camargo P . Peri-implant diseases and conditions: Consensus report of workgroup 4 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018; 45 Suppl 20:S286-S291. DOI: 10.1111/jcpe.12957. View

20.

Tsao C, Darby I, Ebeling P, Walsh K, OBrien-Simpson N, Reynolds E . Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013; 71(8):1360-6. DOI: 10.1016/j.joms.2013.02.016. View